INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.
INTRODUCTION:People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.
Authors: Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown Journal: J Natl Cancer Inst Date: 2011-01-12 Impact factor: 13.506
Authors: J P Mackenbach; G J Borsboom; W J Nusselder; C W Looman; C T Schrijvers Journal: J Epidemiol Community Health Date: 2001-09 Impact factor: 3.710
Authors: Kenneth C Johnson; Anthony B Miller; Neil E Collishaw; Julie R Palmer; S Katharine Hammond; Andrew G Salmon; Kenneth P Cantor; Mark D Miller; Norman F Boyd; John Millar; Fernand Turcotte Journal: Tob Control Date: 2010-12-08 Impact factor: 7.552
Authors: G P Browman; G Wong; I Hodson; J Sathya; R Russell; L McAlpine; P Skingley; M N Levine Journal: N Engl J Med Date: 1993-01-21 Impact factor: 91.245
Authors: J Michael Underwood; Sun Hee Rim; Temeika L Fairley; Eric Tai; Sherri L Stewart Journal: Cancer Causes Control Date: 2012-05-16 Impact factor: 2.506
Authors: Diana S Hoover; Claire A Spears; Damon J Vidrine; Joan L Walker; Ya-Chen Tina Shih; David W Wetter Journal: Am J Health Behav Date: 2019-05-01
Authors: M Shayne Gallaway; Bin Huang; Quan Chen; Thomas C Tucker; Jaclyn K McDowell; Eric Durbin; Sherri L Stewart; Eric Tai Journal: J Community Health Date: 2019-06
Authors: Yael R Symes; Kurt M Ribisl; Marcella H Boynton; J Lee Westmaas; Deborah K Mayer; Shelley D Golden Journal: J Cancer Surviv Date: 2019-01-24 Impact factor: 4.442
Authors: Sapna Kaul; Jaqueline C Avila; Daniel Jupiter; Ana M Rodriguez; Anne C Kirchhoff; Yong-Fang Kuo Journal: J Cancer Res Clin Oncol Date: 2017-08-22 Impact factor: 4.553
Authors: David A Siegel; S Jane Henley; Jennifer M Wike; A Blythe Ryerson; Christopher J Johnson; Judy R Rees; Lori A Pollack Journal: Cancer Date: 2018-03-26 Impact factor: 6.860
Authors: S Jane Henley; Shayne Gallaway; Simple D Singh; Mary Elizabeth O'Neil; Natasha Buchanan Lunsford; Behnoosh Momin; Thomas B Richards Journal: J Womens Health (Larchmt) Date: 2018-10-12 Impact factor: 2.681
Authors: Stephanie R Land; Graham W Warren; Jennifer L Crafts; Dorothy K Hatsukami; Jamie S Ostroff; Gordon B Willis; Veronica Y Chollette; Sandra A Mitchell; Jasmine N M Folz; James L Gulley; Eva Szabo; Thomas H Brandon; Sonia A Duffy; Benjamin A Toll Journal: Cancer Date: 2016-03-28 Impact factor: 6.860
Authors: Eric W Tai; Gery P Guy; C Brooke Steele; S Jane Henley; Michael S Gallaway; Lisa C Richardson Journal: Am J Prev Med Date: 2018-02-01 Impact factor: 5.043